Cargando…

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry

Tau protein concentration in cerebrospinal fluid (CSF) is currently used as a sensitive and specific biomarker for Alzheimer's disease. Its detection currently relies on ELISA but the perspective of using mass spectrometry (MS) to detect its different proteoforms represents an interesting alter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bros, Pauline, Vialaret, Jérôme, Barthelemy, Nicolas, Delatour, Vincent, Gabelle, Audrey, Lehmann, Sylvain, Hirtz, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555028/ https://www.ncbi.nlm.nih.gov/pubmed/26388715 http://dx.doi.org/10.3389/fnins.2015.00302

Ejemplares similares

From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid
por: Hirtz, Christophe, et al.
Publicado: (2016)

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
por: Hirtz, Christophe, et al.
Publicado: (2023)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
por: Mohaupt, Pablo, et al.
Publicado: (2023)

Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches
por: Vialaret, Jerome, et al.
Publicado: (2018)

New Perspectives of Multiplex Mass Spectrometry Blood Protein Quantification on Microsamples in Biological Monitoring of Elderly Patients
por: Vialaret, Jérôme, et al.
Publicado: (2023)

The alternative proteome in neurobiology
por: Mohaupt, Pablo, et al.
Publicado: (2022)

Proteomics Challenges for the Assessment of Synuclein Proteoforms as Clinical Biomarkers in Parkinson’s Disease
por: Pons, Marie-Laure, et al.
Publicado: (2022)

β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer’s disease
por: Mohaupt, Pablo, et al.
Publicado: (2022)

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
por: Darlix, Amélie, et al.
Publicado: (2019)

Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy
por: Dauvilliers, Yves A., et al.
Publicado: (2014)

MRI-Visible Perivascular Spaces Associated With Cognitive Impairment in Military Veterans With Traumatic Brain Injury Mediated by CSF P-Tau
por: Wang, Ming-Liang, et al.
Publicado: (2022)

Hepcidin and ferritin levels in restless legs syndrome: a case–control study
por: Chenini, Sofiene, et al.
Publicado: (2020)

CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
por: Horie, Kanta, et al.
Publicado: (2022)

The Seven Selves of Dementia
por: Bomilcar, Iris, et al.
Publicado: (2021)

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ(1–42) and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2018)

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß(1−42), and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2019)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Factitious Disorder in Seven Patients: A Saudi Experience
por: Qasim, Salman S, et al.
Publicado: (2021)

An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS
por: Self, Wade, et al.
Publicado: (2022)

Proteomic Analysis of Preoperative CSF Reveals Risk Biomarkers of Postoperative Delirium
por: Han, Yongzheng, et al.
Publicado: (2020)

Loss of tau rescues inflammation-mediated neurodegeneration
por: Maphis, Nicole, et al.
Publicado: (2015)

The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice
por: Brelstaff, Jack, et al.
Publicado: (2015)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

A Tangled Web – Tau and Sporadic Parkinson's Disease
por: Wray, Selina, et al.
Publicado: (2010)

Tau: The Center of a Signaling Nexus in Alzheimer's Disease
por: Khan, Shahzad S., et al.
Publicado: (2016)

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
por: Horie, Kanta, et al.
Publicado: (2023)

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
por: Wellington, Henrietta, et al.
Publicado: (2018)

Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases
por: Belbin, Olivia, et al.
Publicado: (2020)

Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges
por: Coppens, Salomé, et al.
Publicado: (2023)

Data from a targeted proteomics approach to discover biomarkers in saliva for the clinical diagnosis of periodontitis
por: Orti, V., et al.
Publicado: (2018)

Simultaneous Quantification of Seven Antifungal Agents in Human Serum Using Liquid Chromatography-Tandem Mass Spectrometry
por: Li, Wenjing, et al.
Publicado: (2023)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

The Metamorphic Nature of the Tau Protein: Dynamic Flexibility Comes at a Cost
por: Sabbagh, Jonathan J., et al.
Publicado: (2016)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

Trends in Bullying and Emotional and Behavioral Difficulties Among Pakistani Schoolchildren: A Cross-Sectional Survey of Seven Cities
por: Naveed, Sadiq, et al.
Publicado: (2020)

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
por: Sato, Chihiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oso291heeg5hlnqsc24qbkm0mg